ClinicalTrials.gg
CompletedNCT03002233Updated Jul 21, 2017

TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus

A Phase 1 interventional study of TRK-820 in Uremic Pruritus, sponsored by Toray Industries, Inc. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by Toray Industries, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.

Enrollment
10th of 10
23 · median 99
Started
2016
the only one that year
Phase 1
Only one
of the 10
Registered
5th of 10
by date
Lead sponsor
3 of 10
Toray Industries, Inc

Among the 10 studies testing TRK 820 in Pruritus, this one is the 10th largest by enrollment, is the only one that started in 2016, is the only one in phase 1, and was the 5th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About TRK 820

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing TRK 820 in Pruritus, or all of them as a file.
02

Study summary

This study is a 2-part study.

Part A is a single-dose, open-label study design to determine the PK, safety and tolerability of 5 μg TRK-820 oral administration in subjects with end-stage renal disease (ESRD) who require hemodialysis.

Part B is a multiple dose, open-label study design to determine the PK, PD, safety and tolerability of multiple doses in subjects with ESRD who require hemodialysis with refractory uremic pruritus (UP). Each subject will receive 3 doses of TRK-820 (2.5, 5 and 10 μg).

03

Conditions studied

  • Uremic Pruritus

Browse trials for

Keywords

  • TRK-820
  • Hemodialysis
  • Uremic Pruritus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult non-smoking male and female subjects (≥ 18 years of age) who have ESRD requiring hemodialysis, at least 3 times a week.
  • Subjects has a clinical diagnosis of UP, which is uncontrolled by current medications or treatments.(Part B only)

Exclusion criteria

Exclusion Criteria:

  • Subject has a known to opioids or the ingredients of the study medication.
  • Subject has pruritus other than related to ESRD (i.e., UP).(Part B only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    TRK-820

    PartA: 5 μg PartB: 2.5-10 μg

    Drug: TRK-820

Interventions

  • Also known as: Nalfurafine Hydrochloride

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters: area under the time curve from time zero to 24 hours postdose(AUC0-24h)

    Time frame: Part A; predose to 24 hours postdose, Part B; predose to 24 hours postdose each dose

  2. Pharmacokinetic parameters: area under the time curve from time zero to the last quantifiable concentration(AUC0-last)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  3. Pharmacokinetic parameters: area under the time curve from time zero extrapolated to infinity(AUC0-inf)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  4. Pharmacokinetic parameters: maximum observed plasma concentration (Cmax)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  5. Pharmacokinetic parameters: time to maximum plasma concentration(Tmax)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  6. Pharmacokinetic parameters: apparent elimination half-life in plasma(t½)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  7. Pharmacokinetic parameters: plasma concentration at 24 hours postdose(C24h)

    Time frame: Part A; 24 hours postdose, Part B; 24 hours postdose each dose

  8. Pharmacokinetic parameters: apparent total clearance(CL/F)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  9. Pharmacokinetic parameters: terminal elimination rate(λz)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  10. Pharmacokinetic parameters: apparent distribution volume(Vz/F)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  11. Pharmacokinetic parameters: mean residence time(MRT)

    Time frame: Part A; predose to 60 hours postdose, Part B; predose to 48 hours postdose each dose

  12. Pharmacodynamic parameters: Visual Analogue Scale (VAS) reduction from baseline

    Time frame: Part B only; Baseline to week 5

07

Study locations

2 sites
  • Bulgaria
    Bulgaria, Bulgaria
  • Germany
    Germany, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2017, 8 months.

Of 21 phase 1 interventional studies under Pruritus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 8 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 23, 2016
StartActual
Nov 2016
Primary completionActual
Jul 2017
CompletionActual
Jul 2017
Last update
Jul 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03002233
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Dec 23, 2016
Start date
Nov 2016
Primary completion
Jul 2017
Completion
Jul 2017
Last update
Jul 21, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK 820

Start the discussion